Cozad Asset Management Inc. Purchases New Holdings in Novartis AG (NVS)

Share on StockTwits

Cozad Asset Management Inc. purchased a new stake in shares of Novartis AG (NYSE:NVS) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 5,532 shares of the company’s stock, valued at approximately $418,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. ST Germain D J Co. Inc. grew its holdings in Novartis by 14.8% during the 2nd quarter. ST Germain D J Co. Inc. now owns 4,765 shares of the company’s stock valued at $360,000 after buying an additional 615 shares in the last quarter. American Research & Management Co. grew its holdings in Novartis by 1.1% during the 2nd quarter. American Research & Management Co. now owns 57,749 shares of the company’s stock valued at $4,362,000 after buying an additional 625 shares in the last quarter. King Luther Capital Management Corp grew its holdings in Novartis by 14.3% during the 2nd quarter. King Luther Capital Management Corp now owns 5,175 shares of the company’s stock valued at $391,000 after buying an additional 649 shares in the last quarter. Wesbanco Bank Inc. grew its holdings in Novartis by 24.2% during the 2nd quarter. Wesbanco Bank Inc. now owns 3,347 shares of the company’s stock valued at $253,000 after buying an additional 653 shares in the last quarter. Finally, Sterling Capital Management LLC grew its holdings in Novartis by 5.3% during the 2nd quarter. Sterling Capital Management LLC now owns 13,127 shares of the company’s stock valued at $992,000 after buying an additional 655 shares in the last quarter. Institutional investors and hedge funds own 11.16% of the company’s stock.

In other news, major shareholder Bioventures Ltd Novartis sold 8,181 shares of Novartis stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $3.22, for a total value of $26,342.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 81,322 shares of company stock valued at $290,796. Company insiders own 0.01% of the company’s stock.

Shares of Novartis stock opened at $85.22 on Friday. The company has a market capitalization of $195.66 billion, a PE ratio of 16.78, a P/E/G ratio of 1.77 and a beta of 0.85. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.15 and a quick ratio of 0.89. Novartis AG has a one year low of $72.30 and a one year high of $94.19.

Novartis (NYSE:NVS) last announced its earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.02. The firm had revenue of $13.16 billion during the quarter, compared to analysts’ expectations of $12.93 billion. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.22 EPS. research analysts forecast that Novartis AG will post 5.17 earnings per share for the current year.

Several research firms have weighed in on NVS. BNP Paribas upgraded Novartis from an “underperform” rating to a “neutral” rating in a report on Tuesday, September 11th. ValuEngine upgraded Novartis from a “sell” rating to a “hold” rating in a report on Wednesday. Exane BNP Paribas upgraded Novartis from an “underperform” rating to a “neutral” rating in a report on Tuesday, September 11th. Citigroup upgraded Novartis from a “neutral” rating to a “buy” rating in a report on Tuesday, September 11th. Finally, Bank of America upgraded Novartis from an “underperform” rating to a “buy” rating and set a $74.71 target price for the company in a report on Monday, September 10th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $87.24.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Further Reading: Discover Your Risk Tolerance

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply